Veeva Systems reported strong QQ2 2025 performance with NOPLAT-like execution in a durable cloud software model for life sciences. Revenue reached $676.2 million, up 14.6% year over year and 3.97% quarter over quarter, supported by a high gross margin of 74.8% and expanding profitability. Net income of $171.0 million and diluted earnings per share of $1.04 (EPS) reflect meaningful margin leverage as the company scales.
Cash generation remained robust, with operating cash flow of $92.9 million and free cash flow of $89.8 million. The balance sheet shows substantial liquidity: cash and cash equivalents of about $1.17 billion and short-term investments of roughly $3.72 billion, resulting in a net cash position of approximately $1.11 billion. Deferred revenue stood at $956.4 million, signaling durable ARR and a favorable revenue recognition profile as Veeva continues to expand its multi-product platform (CRM, Vault, OpenData/Data Cloud) across geographies.
Profitability continued to improve versus prior periods, with operating income of $166.5 million (operating margin ~24.6%) and EBITDA of $177.5 million (EBITDA margin ~26.3%). The quarter reinforces Veeva’s position as a mission-critical SaaS provider for life sciences, underpinned by a high-value product suite and strong cross-sell dynamics. Management commentary was not provided in the dataset; the outlook is framed by sustained demand for cloud-based life sciences solutions and continued investment in product development and go-to-market initiatives, supporting mid-to-high single-digit to mid-teens revenue growth over the near term depending on macro conditions.